Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants

• 主要な著者: Agnes Hincelin‐Mery (著者), Xavier Nicolas (著者), Cathy Cantalloube (著者), Robert Pomponio (著者), Pascale Lewanczyk (著者), Myriam Benamor (著者), Dimitry Ofengeim (著者), Emmanuel Krupka (著者), Jennifer Hsiao‐Nakamoto (著者), Amy Eastenson (著者), Nazem Atassi (著者)
• フォーマット: 図書
• 出版事項: Wiley, 2024-01-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Abstract SAR443820 (DNL788) is a selective, orally bioavailable, brain penetrant inhibitor of receptor‐interacting serine/threonine protein kinase 1 (RIPK1). This phase I first‐in‐human healthy participant study (NCT05795907) was comprised of three parts: randomized, double‐blind, placebo‐controlled...